JP2024514506A5 - - Google Patents
Info
- Publication number
- JP2024514506A5 JP2024514506A5 JP2023560513A JP2023560513A JP2024514506A5 JP 2024514506 A5 JP2024514506 A5 JP 2024514506A5 JP 2023560513 A JP2023560513 A JP 2023560513A JP 2023560513 A JP2023560513 A JP 2023560513A JP 2024514506 A5 JP2024514506 A5 JP 2024514506A5
- Authority
- JP
- Japan
- Prior art keywords
- met
- squamous
- pharmaceutical composition
- tumors
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163171571P | 2021-04-06 | 2021-04-06 | |
| US202163171536P | 2021-04-06 | 2021-04-06 | |
| US63/171,536 | 2021-04-06 | ||
| US63/171,571 | 2021-04-06 | ||
| PCT/US2022/023629 WO2022216796A1 (en) | 2021-04-06 | 2022-04-06 | Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514506A JP2024514506A (ja) | 2024-04-02 |
| JP2024514506A5 true JP2024514506A5 (enExample) | 2025-02-25 |
Family
ID=83510391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560513A Pending JP2024514506A (ja) | 2021-04-06 | 2022-04-06 | テリソツズマブベドチンを使用した非小細胞肺がんの治療方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12433951B2 (enExample) |
| EP (1) | EP4319811A1 (enExample) |
| JP (1) | JP2024514506A (enExample) |
| AU (1) | AU2022253888B2 (enExample) |
| BR (1) | BR112023020562A2 (enExample) |
| CA (1) | CA3214989A1 (enExample) |
| MX (1) | MX2023011733A (enExample) |
| WO (1) | WO2022216796A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20260015178A (ko) * | 2023-05-23 | 2026-02-02 | 애브비 매뉴팩처링 매니지먼트 언리미티드 컴퍼니 | 항-c-met 항체 약물 접합체를 이용한 치료 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2014681A1 (en) | 2007-07-12 | 2009-01-14 | Pierre Fabre Medicament | Novel antibodies inhibiting c-met dimerization, and uses thereof |
| US8545839B2 (en) | 2008-12-02 | 2013-10-01 | Pierre Fabre Medicament | Anti-c-Met antibody |
| WO2010064089A1 (en) | 2008-12-02 | 2010-06-10 | Pierre Fabre Medicament | Novel anti-cmet antibody |
| AR074439A1 (es) | 2008-12-02 | 2011-01-19 | Pf Medicament | Anticuerpo anti-cmet (receptor c-met) |
| EP2402370A1 (en) | 2010-06-29 | 2012-01-04 | Pierre Fabre Médicament | Novel antibody for the diagnosis and/or prognosis of cancer |
| WO2017186928A1 (en) | 2016-04-29 | 2017-11-02 | Curevac Ag | Rna encoding an antibody |
| HUE053332T2 (hu) | 2016-05-17 | 2021-06-28 | Abbvie Biotherapeutics Inc | Anti-cMet-antitest-gyógyszer konjugátumok és eljárások alkalmazásukra |
| US20210393793A1 (en) | 2018-09-26 | 2021-12-23 | Genmab A/S | Axl-specific antibodies for treatment of non-small cell lung cancer |
| WO2021007428A2 (en) * | 2019-07-09 | 2021-01-14 | The Johns Hopkins University | Molecules, compositions and methods for treatment of cancer |
-
2022
- 2022-04-06 BR BR112023020562A patent/BR112023020562A2/pt unknown
- 2022-04-06 EP EP22785354.6A patent/EP4319811A1/en active Pending
- 2022-04-06 JP JP2023560513A patent/JP2024514506A/ja active Pending
- 2022-04-06 WO PCT/US2022/023629 patent/WO2022216796A1/en not_active Ceased
- 2022-04-06 US US17/714,724 patent/US12433951B2/en active Active
- 2022-04-06 CA CA3214989A patent/CA3214989A1/en active Pending
- 2022-04-06 AU AU2022253888A patent/AU2022253888B2/en active Active
- 2022-04-06 MX MX2023011733A patent/MX2023011733A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Greinix et al. | Progressive improvement in cutaneous and extracutaneous chronic graft-versus-host disease after a 24-week course of extracorporeal photopheresis—results of a crossover randomized study | |
| Kebriaei et al. | Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation | |
| JP2011505336A (ja) | 骨髄異形成症候群治療のためのシチジンアナログ | |
| WO2014142220A1 (ja) | 抗腫瘍剤 | |
| Thaker et al. | OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer | |
| Vendrely et al. | Anti-epidermal growth factor receptor therapy in combination with chemoradiotherapy for the treatment of locally advanced anal canal carcinoma: Results of a phase I dose-escalation study with panitumumab (FFCD 0904) | |
| EP3436073A1 (en) | A composition comprising pic for treatment of cancer | |
| CN108503676B (zh) | 用于癌症治疗的果糖类似物及其组合物 | |
| CN115177620A (zh) | 西奥罗尼或其药学上可接受的盐在制备预防或治疗滤泡淋巴瘤的药物中的应用 | |
| CN113440533A (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
| Vermorken et al. | 5501 ORAL Cetuximab plus platinum-based therapy first-line in recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety results of a randomized phase III trial (EXTREME) | |
| EP2663318B1 (en) | Pharmaceutical composition for treating cancer | |
| Matsuzawa et al. | 46P Multi-center, phase II study of docetaxel (DTX) plus ramucirumab (RAM) following platinum-based chemotherapy plus ICIs in patients with NSCLC: SCORPION study | |
| Kako et al. | Safety and efficacy of once-daily intravenous busulfan in allogeneic transplantation: a matched-pair analysis | |
| Degen et al. | Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers? | |
| Bokemeyer et al. | 6079 Overall survival of patients with KRAS wild-type tumours treated with FOLFOX4±cetuximab as 1st-line treatment for metastatic colorectal cancer: The OPUS study | |
| UA128583C2 (uk) | Способи лікування псоріазу | |
| CN113117088B (zh) | 钙激活氯离子通道的抑制剂在肿瘤免疫疗法中的应用 | |
| CN109481687B (zh) | 用于胃癌治疗的cdk4/6抑制剂联合her2抑制剂的组合 | |
| KR20220100006A (ko) | 다중 표적 단백질 키나제 억제제의 용도 | |
| US20220378879A1 (en) | Application of peg interferon and protooncogene product targeting inhibitor in synergistic treatment of renal carcinoma | |
| US20200268703A1 (en) | Medicine for treating advanced or recurrent cancer patient being non-responsive or non-tolerant to standard chemotherapy and incurable and unresectable | |
| Cardoso et al. | 5004 Multicenter phase I clinical trial of daily and weekly everolimus (RAD001) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab | |
| US20240325529A1 (en) | Medicament for treatment and/or prevention of cancer | |
| Sowmiya et al. | Gene therapy breakthroughs in leukemia treatment and future prospects |